Catalent VAI update addresses Brussels shutdown concerns, says Morgan Stanley

Morgan Stanley analyst Tejas Savant noted that Catalent’s Brussels facility is now classified under VAI status, or "voluntary action indicated", on the FDA dashboard, which takes the risk related to a shutdown at Brussels "off the table," in the analyst’s view. This news comes on the heels of a similar VAI status for the Bloomington site, which Savant said is supportive of the company’s efforts to work through quality issues at both locations while "mitigating the risk of manufacturing disruptions." Savant has an Overweight rating and $81 price target on Catalent shares.